At JPM25, Nvidia announced four new partnerships focused on scaling AI models across the healthcare industry. The company is teaming up with Mayo Clinic, Illumina, IQVIA and Arc Institute.
In an interview, Zelis CEO Amanda Eisel shared her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
In a sit-down interview at the annual J.P. Morgan Healthcare conference, Allen talked about a tool built by a company backed by General Catalyst and Andreessen Horowitz.
Johnson & Johnson's agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines.
There was a slight decrease in 2024 digital health venture funding compared to 2023, according to a new report from Rock Health. This partially due to increasing investor interest in earlier-stage startups.
Health systems preparing for an M&A, or even those not immediately considering one, must prioritize a robust workforce data strategy. This approach is essential for navigating today's increasingly frequent healthcare consolidations.
AI is the next big thing, and most developers want to protect those programs and systems. The answer is intellectual property protection and specifically patent protection.
In this episode, we're joined by Kathryn Schubert, president and CEO of the Society for Women's Health Research. Schubert discusses the trends in women's health that defined 2024 and what we can expect in the coming year.
No comments